Development of the Revised Opioid Risk Tool to Predict Opioid Use Disorder in Patients with Chronic Nonmalignant Pain

Overview

Journal J Pain

Specialties Neurology
Psychiatry

Date 2019 Jan 29

PMID 30690168

Citations 29

Authors

Martin D Cheatle

Peggy A Compton

Lara Dhingra

Thomas E Wasser

Charles P OBrien

Affiliations

Soon will be listed here.

Abstract

The Opioid Risk Tool (ORT) is a commonly used measure of risk of aberrant drug-related behaviors in patients with chronic pain prescribed opioid therapy. In this study, the discriminant predictive validity of the ORT was evaluated in a unique cohort of patients with chronic nonmalignant pain (CNMP) on long-term opioid therapy who displayed no evidence of developing an opioid use disorder (OUD) and a sample of patients with CNMP who developed an OUD after commencing opioid therapy. Results revealed that the original ORT was able to discriminate between patients with and without OUDs (odds ratio = 1.624; 95% confidence interval [CI] = 1.539-1.715, P < .001). A weighted ORT eliminating the gender-specific history of preadolescent sexual abuse item revealed comparable results (odds ratio = 1.648, 95% CI = 1.539-1.742, P < .001). A revised unweighted ORT removing the history of preadolescent sexual abuse item was notably superior in predicting the development of OUD in patients with CNMP on long-term opioid therapy (odds ratio = 3.085; 95% CI = 2.725-3.493; P < .001) with high specificity (.851; 95% CI = .811-.885), sensitivity (.854; 95% CI = .799-.898), positive predictive value (.757; 95% CI = .709-.799), and negative predictive value (.914; 95% CI = .885-.937). Perspective: The revised ORT is the first tool developed on a unique cohort to predict the risk of developing an OUD in patients with CNMP receiving opioid therapy, as opposed to aberrant drug-related behaviors that can reflect a number of other issues. The revised ORT has clinical usefulness in providing clinicians a simple, validated method to rapidly screen for the risk of developing OUD in patients on or being considered for opioid therapy.

Citing Articles

A New Neuroanesthetic Protocol of Rendering Specialized Care in Treating Degenerative Lumbar Spine Diseases in High-Risk Patients: Prospective Analysis of the Results.

Kalinin A, Goloborodko V, Pestryakov Y, Kundubayev R, Biryuchkov M, Shchegolev A Sovrem Tekhnologii Med. 2024; 16(3):51-59.

PMID: 39650272 PMC: 11618530. DOI: 10.17691/stm2024.16.3.06.

Consensus statement on chronic pain treatment in cancer survivors.

Mamiya K, Iida H, Iseki M, Yamaguch S, Yonekura H, Ueno H J Anesth. 2024; .

PMID: 39627504 DOI: 10.1007/s00540-024-03427-0.

Toward a Psychological Model of Chemical Coping with Opioids in Cancer Care.

Yusufov M, Pirl W, Braun I, Sannes T, McHugh R Harv Rev Psychiatry. 2023; 31(6):259-266.

PMID: 37948154 PMC: 11060627. DOI: 10.1097/HRP.0000000000000384.

Opioid use disorder in two samples of the Lebanese population: scale validation and correlation with sleep and mood disorders.

Chamoun K, Mouawad J, Salameh P, Sacre H, Haddad R, Khabbaz L BMC Psychiatry. 2023; 23(1):797.

PMID: 37914993 PMC: 10619223. DOI: 10.1186/s12888-023-05304-8.

An opioid-minimizing multimodal pain regimen reduces opioid exposure and pain in trauma-injured patients at high risk for opioid misuse: Secondary analysis from the mast trial.

de Dios C, Suchting R, Green C, Klugh J, Harvin J, Webber H Surgery. 2023; 174(6):1463-1470.

PMID: 37839970 PMC: 10836717. DOI: 10.1016/j.surg.2023.09.011.

References

Kendler K, Bulik C, Silberg J, Hettema J, Myers J, Prescott C . Childhood sexual abuse and adult psychiatric and substance use disorders in women: an epidemiological and cotwin control analysis. Arch Gen Psychiatry. 2000; 57(10):953-9. DOI: 10.1001/archpsyc.57.10.953. View

Butler S, Budman S, Fernandez K, Jamison R . Validation of a screener and opioid assessment measure for patients with chronic pain. Pain. 2004; 112(1-2):65-75. DOI: 10.1016/j.pain.2004.07.026. View

Webster L, Webster R . Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005; 6(6):432-42. DOI: 10.1111/j.1526-4637.2005.00072.x. View

Belgrade M, Schamber C, Lindgren B . The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006; 7(9):671-81. DOI: 10.1016/j.jpain.2006.03.001. View

Butler S, Budman S, Fernandez K, Houle B, Benoit C, Katz N . Development and validation of the Current Opioid Misuse Measure. Pain. 2007; 130(1-2):144-56. PMC: 1950245. DOI: 10.1016/j.pain.2007.01.014. View

Chou R, Fanciullo G, Fine P, Adler J, Ballantyne J, Davies P . Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2):113-30. PMC: 4043401. DOI: 10.1016/j.jpain.2008.10.008. View

Chou R, Ballantyne J, Fanciullo G, Fine P, Miaskowski C . Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009; 10(2):147-59. DOI: 10.1016/j.jpain.2008.10.007. View

Moore T, Jones T, Browder J, Daffron S, Passik S . A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med. 2009; 10(8):1426-33. DOI: 10.1111/j.1526-4637.2009.00743.x. View

Cheatle M, OBrien C . Opioid therapy in patients with chronic noncancer pain: diagnostic and clinical challenges. Adv Psychosom Med. 2011; 30:61-91. DOI: 10.1159/000324067. View

10.

Jones T, Moore T, Levy J, Daffron S, Browder J, Allen L . A comparison of various risk screening methods in predicting discharge from opioid treatment. Clin J Pain. 2011; 28(2):93-100. DOI: 10.1097/AJP.0b013e318225da9e. View

11.

Jones T, Passik S . A comparison of methods of administering the opioid risk tool. J Opioid Manag. 2011; 7(5):347-51. DOI: 10.5055/jom.2011.0075. View

12.

Jones T, Moore T . Preliminary data on a new opioid risk assessment measure: the Brief Risk Interview. J Opioid Manag. 2013; 9(1):19-27. DOI: 10.5055/jom.2013.0143. View

13.

OConnor A, Turk D, Dworkin R, Katz N, Colucci R, Haythornthwaite J . Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations. Pain. 2013; 154(11):2324-2334. DOI: 10.1016/j.pain.2013.06.035. View

14.

Cheatle M, OBrien C, Mathai K, Hansen M, Grasso M, Yi P . Aberrant behaviors in a primary care-based cohort of patients with chronic pain identified as misusing prescription opioids. J Opioid Manag. 2013; 9(5):315-24. DOI: 10.5055/jom.2013.0174. View

15.

Jones T, Lookatch S, Grant P, McIntyre J, Moore T . Further validation of an opioid risk assessment tool: the Brief Risk Interview. J Opioid Manag. 2014; 10(5):353-64. DOI: 10.5055/jom.2014.0226. View

16.

Smith S, Paillard F, McKeown A, Burke L, Edwards R, Katz N . Instruments to Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: An ACTTION Systematic Review. J Pain. 2015; 16(5):389-411. PMC: 5460153. DOI: 10.1016/j.jpain.2015.01.009. View

17.

Jones T, Lookatch S, Moore T . Validation of a new risk assessment tool: the Brief Risk Questionnaire. J Opioid Manag. 2015; 11(2):171-83. DOI: 10.5055/jom.2015.0266. View

18.

Dowell D, Haegerich T, Chou R . CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016; 65(1):1-49. DOI: 10.15585/mmwr.rr6501e1. View

19.

Busse J, Craigie S, Juurlink D, Buckley D, Wang L, Couban R . Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017; 189(18):E659-E666. PMC: 5422149. DOI: 10.1503/cmaj.170363. View

20.

Hah J, Sturgeon J, Zocca J, Sharifzadeh Y, Mackey S . Factors associated with prescription opioid misuse in a cross-sectional cohort of patients with chronic non-cancer pain. J Pain Res. 2017; 10:979-987. PMC: 5422534. DOI: 10.2147/JPR.S131979. View